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1039-59 Simvastatin Preserves tiyocardial Function by 
Enhancing Endothelial Nitric Oxide Production in Heart 
Failure 
Seena S. Abraham Juan C. Osorio, Jie Wang, James K. Liao, Shunichi Homma. Seema 
Mital. The New York-Presbyterian Hospital. New York, NY, Brigham 8 Women’s 
Hospital. Boston, MA 
Background: Endothelial nitric oxide synthase (ENOS) is reduced in heart failure (HF). 
Statins upregulate NO production independent of lipid-lowering. We evaluated the ability 
of simvastatin (Sim) lo reverse ventricular remodeling and dysfunction by restoring coro- 
nary NO production and NO mediated regulation of apoptosis. 
Methods: Five month old cardiomyopathic (CMP) hamsters were divided into 2 groups - 
Sim (n=5), and Untreated (n=5). Age-matched normal hamsters ware used as controls 
(n=6). Sim group received 20 “g/kg Sim daily by oral gavage for 6 weeks. Serial 2D 
echocardiograms were obtained at baseline and 2 week intervals. LV function and 
dimensions indexed lo body surface area were compared between groups. Myocardial 
apoptosis was evaluated by immunostaining and caspasa 3 activity assay. Myocardial 
ENOS expression was measured by Western blot and immunohistochemistry. 
Results: At baseline, CMP hamsters had lower LV shortening fraction (SF) compared to 
controls (17*2% vs.59+2%), higher LV diastolic volume (30*2 vs.6iO.5 ml/m*) and lower 
LV mass/volume ratio (0.5iO.02 vs. 0.72t0.02 “g/ml, p<O.OOl). Untreated CMP ham- 
sters demonstrated a progressive decrease in LVSF (12*1%, ~~0.05) and increase in LV 
volume from baseline (37*2 ml/m2, ~~0.05). The Sim group showed no deterioration in 
LV function (SF 18+.1%) or LV dilatation (LV volume, 26*2 “!I”‘, p<O.O5) compared to 
the untreated group. lmmunostainina revealed a hiaher percentaae of apoptotic nuclei in _ _ 
the HF group compared to controls (&096*0.04% vs.O.O32+0.02%, ~‘0.002). Caspase 3 
activity was lower in the Sim cornoared to the untreated orouo f1~0.001). lnhibitina -... , ” 
endogenous NO increased caspase 3 activity in the Sim (p=O.O5) but not in the untreated 
group. Myocardial ENOS staining revealed increased capillary density per 3 high power 
fields in the Sim (llOil2. pqO.05) compared to controls (47*9) and untreated hamsters 
(56ill). 
Conclusions: Sim administration preserves myocardial function, decreases LVremodel- 
ing and retards the progression of HF. This may be related to an increase in coronary 
microvasculature resulting in increased endothelial NO availability and reduced cardi- 
omyocyte apoptosis. 
1039-60 Pregnancy-Associated Cardiomyopathy: Early Versus 
Late Presentation 
Mohammed W. Akhter, Avraham Shotan, Afshan Hameed, Harpreet Singh, Salman 
Khan, Usman Ahsan, Muhammad T. Khan, Uri Elkayam, University of Southern 
California, Los Angeles, CA 
Background: Initial diagnostic criteria have limited Pregnancy associated cardiomyopa- 
thy (PACM) to last month of gestation or 5 months after delivery. These criteria however, 
were established 4 decades ago and may have been limited by inferior diagnostic capa- 
bilities and small number of patients. We have therefore reexamined the timing of symp- 
toms onset as well as diagnosis I” 137 patients (pts) recently diagnosed with PACM. 
Methods: We reviewed records of 137 pts with PACM with the following criteria: 1. 
Development of heart failure (HF) during pregnancy or first 6 months postpartum (PP), 2. 
Absence of identifiable cause of HF, 3. Depressed ejection fraction (EF)< 40 %. 
Results: Timing of symptoms onset and diagnosis were as follows: 
TIME ~27 28-36 37-40 1 MONTH 2-6 MONTHS 
WEEKS WEEKS WEEKS PP PP 
Symptoms 8% 21% 6% 58% 7% 
onset 
Diagnosis 3% 13% 6% 62% 16% 
PACM was diagnosed early (~37 weeks) I” 20 pts and late c> 37 weeks) in 102 pts. 
There was no difference in age (30 f 6 vs 31 * 6 years, p=O.74), gravity (2.5 5 6.3 vs 2.7 
* 2.3, p=O.65) or EF both at time of diagnosis (32 * 11% YS 31 + 12%, p=O.93) and follow 
up of 26 months (44 * 16% vs 45 + 15%, p=O.53) between the 2 groups. 
Conclusions Although PACM mostly presents during the first month PP, almost 30% of 
cases present during the 2nd and 3rd trimester prior to last gestational month. Increased 
awareness of early presentation of PACM is important to allow early diagnosis and 
appropriate care of this potentially life threatening condition. 
ABSTRACTS - Cardiac Function and Heart Failure 151A 
1039-61 Predictors of In-Patient Mortality Following Emergency 
Heart Failure Hospitalization 
Colin Berry, Michael Brett, Karen Stevenson, John Norrie, John McMurray, University of 
Glasgow, Glasgow, United Kingdom 
Introduction: Much of the information on heart failure (HF) has been derived from clinical 
trials. We sought to determine the characteristics which may be associated with suwival 
in ‘real-life’, hospitalized, HF patients. 
Methods: We examined the clinical characteristics and predictors of in-hospital case- 
fatality in 547 consecutive emergency admissions with HF to one acute urban University 
hospital over 1 year period. 
F&sub: Average age was 72 (SD 13) years, 49% were male and 476 patients (87%) sur- 
vived lo discharge. 414 (75%) had an echocardiogram. of whom 133 (32%) had pre- 
served left ventricular systolic function (LVSF). Mean hemoglobin (Hb) concentration was 
12.5*2.1 g/dL in males and 12.Okl.9 g/dL in females. 52% of man and 37% of women 
were anemic (normal range man Hb 13 - 18 g/dL, women Hb 11.5 - 16.5g/dL). The % of 
man with Hb < 13, 12, 11, 10 g/dl was 16. 14. 10 and 12% respectively (women, % Hb < 
11.4, 10.4, 9.4 and 8.4 g/dl was 21, 8, 6 and 3%). Mean white cell count (WCC) was 9.24 
x 109/L (4-l 1 x 109/L). and 22% of patients had low WCC. Mean lymphocyte count (LC) 
wasl.6 x 109/L and 58% of patients had a low LC. In-patient case fatality rate tended to 
be higher for patients with impaired LVSF, compared to preserved LVSF (13% YS 8%; 
P=O.OG).The probability of being alive at discharge was increased by treatment with an 
ACE inhibitor (odds ratio (OR) 1 .l, 95% Cl 1.0-1.2: P=O.O2) or an HMG CoA reductase 
inhibitor (OR 1.1, Cl 1.0-1.2; P=O.O04). A higher Hb concentration was also positively 
associated with survival (OR 1.03 per g/dL, Cl 1.0-l .05; P~0.02). Factors associated with 
an increased risk of death during admission were the presence of renal dysfunction (OR 
1.2, Cl 1 .1-l .3: P=O.Ol) and ischemic chest pain (OR 1.2, Cl 1.1-l .3; P= 0.001). Diabe- 
tes (OR 1.1; Cl 0.97-l .2; P=O.2) and an elevated C-reactive protein concentration (OR 
1.01; Cl 1 .OO-1.02; P=O.O8) tended to be associated with an increased risk of death. 
Conclusion: Both low WCCILC (by increasing the risk of infection) and low Hb may con- 
tribute to HF decompensation. Statin therapy and Hb concentration may be two new 
markers of shorl term prognosis. The potentially protective effects of a higher Hb and sta- 
tin therapy merit prospective investigation in HF. 
1039-62 Impact of Peripheral Endothelial Vasomotor Function 
on Exercise Capacitv and Adhesion Molecules in 
ldiopathlc Dilated Cardiomyopathy 
Barbara M. Richariz, Friedhelm Kuethe, Hans R. Figulla, Gerald S. Werner, Friedrich- 
Schiller-University Jena, Jena. Germany 
Background: Exercise tolerance- which has been linked to impaired blood perfusion of 
skeletal muscles _ varies significantly between patients with hearl failure. Recent studies 
have shown endothelial dysfunction of peripheral resistance arteries and an impaired 
flow-dependent-dilation (FDD) of conduit vessels. This study was designed to determine 
the degree of impaired FDD on exercise capacity and endothelial activation. 
Methods In 38 patients with idiopathic dilated cardiomyopathy (IDC) longitudinal radial 
artery images were obtained with a high-resolution (10 MHz) vascular transducer. FDD 
was determined by maximal radial diameter after exactly 60 s of reactive hyperemia com- 
pared to baseline vessel diameter. FDD was defined as a change > 5%. Serum concen- 
trations of ICAM- and VCAM-1 were analyzed by ELISA. The severity of heart failure 
was assessed in accordance to NYHA-classification. hemodynamic parameters (pulmo- 
nary capillary wedge pressure. I& ventricular ejection fraction). and peak oxygen con- 
sumption. 
Results: Two distinct patterns of peripheral FDD could be distinguished: In 21 patients 
(group 1, 55%) radial artery dilates in response to reactive hyperemia, whereas in 17 
patients (group 2, 45%) impaired FDD was observed implicating endothelial dysfunction 
(for details cf. table). 
FDD (mm) 
LVEF (%) 
PCWP (mmHg) 
V02 (ml/min/kg) 
VCAM-1 @g/ml) 
ICAM- (pgiml) 
NYHA 
Group 1 Group 2 
+0.55 io.17 +0.04 -+ 0.11 
2428 2829 
2227 1727 
2225 1423 
333 121 + 478 2149 
218 134 + 342 _+129 
2.2 io.3 2.9 io.3 
p-value 
<0.05 
NS 
NS 
co.05 
co.05 
co.05 
0.065 
Conclusions: The severity of heart failure in IDC and thus exercise intolerance is closely 
linked to peripheral endothelium vasomotor dysfunction and accompanied by endothelial 
activation. 
1039-63 Clonal T-Cell Composition Detected by Family Specific 
Polymerase Chain Reaction of the T-Cell Receptor Beta 
Chain Is Exclusively Present in Dilated Cardiomyopathy 
Michel Noutsias Jan H. Blohm, Chalid Assaf, Nadine Bigdeli-lssazadeh, Michael 
Hummel, Rabat S. Warraich, Magdi H. Yacoub, Harald Stein. Heinz P. Schultheiss, 
Matthias Pauschinger, UKBF, Free University, Berlin, Germany, NHLI, Harefield 
Hospital, Middlesex, United Kingdom 
Background: Autoimmunity, resulting from molecular mimicry between viral and cryptic 
cardiac antigens. is postulated for the pathogenesis of dilated cardiomyopathy (DCM). 
Autoimmunity directed against distinct antigens evokes expansion of specific T-cell 
clones infiltrating the target tissue. This phenomenon leads to a clonal predominance of 
T-cells harboring an identical rearranged T-cell receptor gene (TCR), which can be reli- 
ably identified by family specific PCR for the WN-DP-N-Jpregion of the TCR gene in 
combination with high-resolution GeneScan-analysis. 
